Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22965627 | 0.89 | DGKA (0.42) | DGKAHTR2CALDH1A1KDM4ETDP1 | |
| SCHEMBL11190223 | 0.87 | DGKA (0.50) | DGKANAAAHTR2CALDH1A1LMNA | |
| SCHEMBL17039296 | 0.79 | DGKA (0.48) | DGKANAAAHTR2CALDH1A1LMNA | |
| SCHEMBL8924852 | 0.79 | EPHX2 (0.38) | DGKAHRH3ADRB2ALDH1A1KDM4E | |
| SCHEMBL5930623 | 0.78 | DGKA (0.60) | DGKANAAAHTR2CALDH1A1MAPT | |
| SCHEMBL421653 | 0.78 | NAAA (0.60) | DGKANAAAHTR2CALDH1A1EPHX2 | |
| SCHEMBL12176701 | 0.78 | CYP1A2 (0.52) | ALDH1A1 | |
| SCHEMBL27847936 | 0.77 | ALDH1A1 (0.44) | DGKAALDH1A1KDM4ETDP1LMNA | |
| SCHEMBL18649182 | 0.77 | ALDH1A1 (0.50) | HRH3ADRB2ALDH1A1KDM4ETDP1 | |
| SCHEMBL17036647 | 0.76 | ALDH1A1 (0.48) | HRH3ADRB2ALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189869-B2 | Amino compounds for treatment of complement mediated disorders | CFD, TFPI, C9 | DGKA 4236/4885HRH3 592/4885ADRB2 2350/4885 |
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | DGKA 2456/4885HRH3 927/4885ADRB2 1016/4885 |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | DGKA 4236/4885HRH3 592/4885ADRB2 2350/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | DGKA 4236/4885HRH3 592/4885ADRB2 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.